NCT01384630View on ClinicalTrials.gov

Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

August 31, 2012

Conditions
Psoriasis
Interventions
DRUG

RA-18C3

200 mg subcutaneous injection

Trial Locations (3)

42303

West Kentucky Dermatology, Owensboro

48109

University of Michigan, Ann Arbor

78746

Westlake Dermatology, Austin

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01384630 - Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis | Biotech Hunter | Biotech Hunter